14 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- BOS172738 A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) Multiple phase 1 Closed Rearranged during transfection(RET) gene altered malignancy
- EORTC 1209-EnTF A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy Thyroïd phase 2 Closed At least 1 or 2 prior lines of treatment
- EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis
- I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy
- IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors
- Intervention destinée aux parents L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité Solid tumors Open Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors
- MCLA-158-CL01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors Multiple phase 1 Open Metastatic, Biopsy mandatory
- NIS-OBE-CAP-2013/1 Caprelsa(r) Registry : A Belgian Registry to evaluate the use of Vandetanib (Caprelsa(r)) in current clinical practice Thyroïd Closed Already received a prescription for vandeanib
- OX2016-203-01 An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Multiple phase 1 Closed Any line/RECIST v1.1/Eligible for platinium salt chemotherapy
- Sevrage Tabagique Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study Solid tumors Open Smoker of quit smoking within the last 6 months, any tumors
- SYD985.004 A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours Multiple phase 1 Closed RECIST v1.1
- XL184-311 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy Thyroïd phase 3 Closed RECIST 1.1